Evidence map›Paper›PMID 34966729›Full record

ReviewFrontiers in bioengineering and biotechnology2021

HEK293 Cell Line as a Platform to Produce Recombinant Proteins and Viral Vectors.

Evan Tan, Cara Sze Hui Chin, Zhi Feng Sherman Lim, Say Kong Ng

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

137 citing papers in PubMed, 225 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Chemical reviews · 2026
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Evan TanBioprocessing Technology Institute, Agency for Science, Technology and Research (ASTAR), Singapore, Singapore.
Cara Sze Hui ChinBioprocessing Technology Institute, Agency for Science, Technology and Research (ASTAR), Singapore, Singapore.
Zhi Feng Sherman LimBioprocessing Technology Institute, Agency for Science, Technology and Research (ASTAR), Singapore, Singapore.
Say Kong NgBioprocessing Technology Institute, Agency for Science, Technology and Research (ASTAR), Singapore, Singapore.
Agency for Science, Technology and Research · SGBioprocessing Technology Institute · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Animal cell-based expression platforms enable the production of complex biomolecules such as recombinant proteins and viral vectors. Although most biotherapeutics are produced in animal cell lines, production in human cell lines is expanding. One important advantage of using human cell lines is the increased potential that the resulting biotherapeutics would carry more "human-like" post-translational modifications. Among the human cell lines, HEK293 is widely utilized due to its high transfectivity, rapid growth rate, and ability to grow in a serum-free, suspension culture. In this review, we discuss the use of HEK293 cells and its subtypes in the production of biotherapeutics. We also compare their usage against other commonly used host cell lines in each category of biotherapeutics and summarise the factors influencing the choice of host cell lines used.

Indexed as

biotechnologybiotherapeutics and biologicsHEK293human embryonic kidney cell 293viral vectored vaccinesviral vectors

Identifiers

PMID34966729
PMCPMC8711270
OpenAlexW4200473483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.